Paper Details

  1. Home
  2. Paper Details

Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma.

Author: BensenAeSoon, BlumbergDylan C, JonasOliver, MillsGordon B, TatarovaZuzana

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A new study explored the use of a multiplex implantable microdevice assay (MIMA) to identify biomarkers predictive of immune checkpoint inhibitor (ICB) efficacy in breast cancer. MIMA involves delivering small amounts of drugs to the tumor bed and analyzing the spatial cell relations of candidate markers using multiplex immunohistochemistry (mIHC). The study found that a combination of galectin-3, ICAM-1, and neuropilin-1, detected in specific tumor zones, was a robust predictor of ICB efficacy. This approach has the potential to identify responders and non-responders quickly, limiting unnecessary toxicities.
Paper Details　
Original Abstract of the Article :
Immunotherapies, including anti-PD-1 immune checkpoint blocking (ICB) antibodies, have revolutionized the treatment of many solid malignancies. However, their efficacy in breast cancer has been limited to a subset of patients with triple-negative breast cancer, where ICBs are routinely combined with...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856407/

データ提供：米国国立医学図書館（NLM）

Panobinostat and Anti-PD-1: A Powerful Duo in the Fight Against Breast Cancer

Immunotherapies, particularly anti-PD-1 checkpoint inhibitors, have revolutionized cancer treatment. However, their efficacy in breast cancer remains limited, particularly in luminal subtypes. This study delves into the synergistic potential of panobinostat, a pan-HDAC inhibitor, when combined with anti-PD-1 therapy in a mouse model of luminal breast cancer. The researchers utilized a novel multiplex implantable microdevice assay (MIMA) to evaluate the spatial distribution and interactions of key biomarkers within the tumor microenvironment, offering valuable insights into the mechanisms of action and potential predictive markers for successful treatment.

Spatial In Situ Biomarkers: A New Map for Personalized Therapy

The researchers identified several spatial biomarkers associated with the efficacy of panobinostat in combination with anti-PD-1 therapy. These biomarkers, including cleaved caspase-3, ICAM-1, neuropilin-1, myeloperoxidase, calreticulin, galectin-3, and PD-L1, provided a detailed snapshot of the immune response within the tumor microenvironment. Their findings suggest that the spatial distribution of these biomarkers, rather than their individual expression levels, might serve as a more reliable predictor of treatment response. It's like discovering a new map in the vast desert of cancer research, revealing hidden pathways and key landmarks for guiding successful treatment strategies.

The Future of Personalized Therapy: Precision Medicine in Breast Cancer

This study opens a new chapter in personalized therapy for breast cancer. The researchers' innovative approach, utilizing spatial biomarkers and MIMA technology, offers a powerful tool for predicting treatment response and tailoring therapies to individual patients. This research provides valuable insights into the complex interactions within the tumor microenvironment, paving the way for a future where precision medicine plays a central role in breast cancer management.

Dr.Camel's Conclusion

This study offers a promising new approach to combating breast cancer, leveraging the power of immunotherapy and precision medicine. By understanding the intricate interplay of spatial biomarkers and immune responses within the tumor microenvironment, we can develop more effective and personalized treatment strategies for this challenging disease.

Date :
  1. Date Completed 2023-01-24
  2. Date Revised 2023-08-14
Further Info :

Pubmed ID

36672243

DOI: Digital Object Identifier

PMC9856407

Related Literature

Article Analysis
・Effects of panobinostat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.